Skip to main content
. Author manuscript; available in PMC: 2016 Aug 15.
Published in final edited form as: Lancet Oncol. 2011 Dec 15;13(2):172–180. doi: 10.1016/S1470-2045(11)70303-5

Table 2.

Protocol Treatment Delivered (n=44)

Type of radiation therapy administered
    3DCRT 1 ( 2.3%)
    IMRT 43 ( 97.7%)
Radiation dose (Gy)
    Median 69.96
    Min - Max 65.72 – 70
    Q1 - Q3 69.96 – 70
Concurrent cisplatin cycles
    2 14 ( 31.8%)
    3 30 ( 68.2%)
Concurrent bevacizumab cycles
    1 1 ( 2.3%)
    2 12 ( 27.3%)
    3 31 ( 70.5%)
Adjuvant cisplatin cycles
    0 11 ( 25.0%)
    1 3 ( 6.8%)
    2 9 ( 20.5%)
    3 21 ( 47.7%)
Adjuvant 5-FU cycles
    0 8 ( 18.2%)
    1 3 ( 6.8%)
    2 9 ( 20.5%)
    3 24 ( 54.5%)
Adjuvant bevacizumab cycles
    0 8 ( 18.2%)
    1 3 ( 6.8%)
    2 10 ( 22.7%)
    3 23 ( 52.3%)

Q1 = first quartile; Q3 = third quartile.